# CMB International Securities | Equity Research | Company Update



#### 招商银行全资附属机构 A Wholly Owned Subsidiary Of China Merchants Bank

# **BYD Electronics (285 HK)**

# Industry headwinds to persist into 4Q; D/G to HOLD

We downgrade BYDE to Hold (from Buy) given challenging 4Q21E outlook on chip shortage and slower iPad/e-cigarette ramp. Mgmt also revised down FY21E revenue guidance to RMB90bn (from RMB100bn), and e-cigarette channel destocking will continue into 4Q21E. We trimmed FY21-23E EPS by 26-35% to reflect chip shortage and lower iPad/e-cigarette sales. While we believe share gain in Xiaomi/iPad OEM, smart/automobile products and e-cigarette ramp will remain growth drivers in FY22-23E, chip shortage and smartphone weakness will negatively impact BYDE's profitability in 4Q21E and FY22E. Our new STOP-based TP of HK\$26.44, implying 13.4x FY22E P/E.

- 3Q21 miss on chip shortage and power outage. BYDE's 3Q21 revenue grew 6% YoY but net profit declined 72% YoY to RMB514mn (vs -54% YoY in 2Q21), 38% below our estimates, mainly due to chip shortage, power outage, and weak smartphone demand. GPM was flattish QoQ at 7.2% in 3Q21 (vs 16.8% in 3Q20) given high-base on mask in 3Q20 and lower utilization with power crunch in Xian/Huizhou facilities in 3Q21. By segment, we estimate handset OEM grew at single-digit YoY and component was flattish both QoQ/YoY in 3Q21, while new/auto intelligent product segment remained strong with 30%+ YoY growth.
- FY21E sales guidance revised down on weaker iPad and e-cigarette. Mgmt. adjusted down FY21E revenue guidance to RMB90bn (vs prior RMB100bn) given chip shortage impact on handset/iPad segments and e-cigarette channel destocking in 2H21E. In particular, we believe BYDE's iPad weakness in 4Q21E is in-line with Apple's cautious guidance on iPad (YoY decline in 4Q) given recent chip shortage. For FY22E, BYDE guided revenue of RMB12-13bn, driven by share gain in iPad OEM/components and mass production of new plants Zhongshan and Vietnam.
- Headwinds to continue into 4Q21E; D/G to HOLD with new TP HK\$26.44. While we remain positive on BYDE's product roadmap, share gain in major brands and expansion into e-cigarette markets in 2022E, we cut FY21-23E EPS by 26-35% to reflect lowered guidance and conservative GPM on chip shortage. Our new SOTP-based TP of HK\$26.44 implies 13.4x FY22E P/E. Trading at 11.8x FY22E P/E, the stock is fairly valued due to uncertainty on profitability and demand headwinds.

### **Earnings Summary**

(YE 31 Dec)	FY19A	FY20A	FY21E	FY22E	FY23E
(TE 3T Dec)	FIIJA	FIZUA	FIZIE	FIZZE	FIZJE
Revenue (RMB mn)	53,028	73,121	89,477	113,572	141,583
YoY growth (%)	29.2	37.9	22.4	26.9	24.7
Net income (RMB mn)	1,598	5,441	2,897	3,677	5,155
EPS (RMB)	0.71	2.41	1.29	1.63	2.29
YoY growth (%)	(25.5)	240.6	(46.8)	27.0	40.2
Consensus EPS (RMB)	NA	NA	1.66	2.28	2.97
P/E (x)	27.1	8.0	14.9	11.8	8.4
P/B (x)	3.7	2.9	2.6	2.3	1.9
Yield (%)	0.4	1.3	0.7	0.8	1.2
ROE (%)	9.4	24.9	11.8	13.2	15.9
Net gearing (%)	Net cash				

Source: Company data, Bloomberg, CMBIS estimates

# **HOLD (Down)**

Target Price HK\$26.44
(Previous TP HK\$49.5)
Up/Downside +14%
Current Price HK\$23.15

### **China Technology Sector**

#### Alex Ng

(852) 3900 0881 alexng@cmbi.com.hk

### Lily Yang

(852) 3916 3716 lilyyang@cmbi.com.hk

### Stock Data

Mkt. Cap. (HK\$mn)	52,162
Avg. 3mths t/o (HK\$mn)	265.65
52W High/Low (HK\$)	63.10/ 22.80
Total Issued Shares (mn)	2,253

Source: Bloomberg

### **Shareholding Structure**

Golden Link Worldwide Ltd	65.76%
Gold Dragonfly Ltd	4.98%
Vanguard Group	1.25%
Source: Bloomberg	

### **Share Performance**

	Absolute	Relative
1-mth	-15.7%	-18.3%
3-mth	-41.1%	-39.7%
6-mth	-44.0%	-36.6%

Source: Bloomberg

### 12-mth Price Performance



Source: Bloomberg

### **Auditor: Ernst & Young**

### Related reports:

- Outlook intact despite NT headwinds; Maintain BUY – 1 Sep 2021
- 2. CMBI Tech Corporate Day takeaways 16 Jun 2021
- 3. Expect margin pressure to ease ahead; Maintain BUY 30 Apr 2021



# **3Q21 Results review**

Figure 1: Quarterly results review

	-						CMBI	9M21	Consensus	9M21
RMB mn	4Q20	1Q21	2Q21	3Q21	YoY	QoQ	FY21E	% Track	FY21E	% Track
Revenue	20,131	19,890	24,641	21,404	6%	-13%	97,307	68%	99,297	66%
Gross profit	3386	1282	1779	1543	-54%	-13%	7,768	59%	8,135	57%
Net profit	1862	808	835	514	-72%	-38%	3,937	55%	3,714	58%
EPS (RMB)	0.82	0.36	0.37	0.23	-72%	-37%	1.75	55%	1.66	58%
Gross margin	16.8%	6.4%	7.2%	7.2%	-9.6 ppt	0 ppt	8.0%		8.2%	
Net margin	9.2%	4.1%	3.4%	2.4%	-6.8 ppt	-1 ppt	4.0%		3.7%	
Revenue (YoY)	33.2%	132.2%	8.0%	6.3%						
Gross profit (YoY)	219.2%	20.4%	-41.4%	-54.4%						
Net profit (YoY)	312.5%	22.9%	-54.0%	-72.4%						

Source: Company data, Bloomberg, CMBIS estimates

# **Earnings Revision**

Figure 2: Earnings revision

DMD mm		New			Old		С	Change (%)			
RMB mn	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E		
Revenue	89,477	113,572	141,583	97,307	117,744	147,850	-8%	-4%	-4%		
Gross Profit	6,710	8,808	11,533	7,768	10,701	13,985	-14%	-18%	-18%		
Operating Profit	2,058	3,016	4,695	3,165	5,250	7,139	-35%	-43%	-34%		
Net profit	2,897	3,677	5,155	3,937	5,643	7,306	-26%	-35%	-29%		
EPS (RMB)	1.29	1.63	2.29	1.75	2.50	3.24	-26%	-35%	-29%		
Gross Margin	7.5%	7.8%	8.1%	8.0%	9.1%	9.5%	-0.5 ppt	-1.3 ppt	-1.3 ppt		
Operating Margin	2.3%	2.7%	3.3%	3.3%	4.5%	4.8%	-1 ppt	-1.8 ppt	-1.5 ppt		
Net Margin	3.2%	3.2%	3.6%	4.0%	4.8%	4.9%	-0.8 ppt	-1.6 ppt	-1.3 ppt		

Sources: Company data, CMBIS estimates

Figure 3: CMBIS estimates vs consensus

DMD		CMBIS			Consensus			Diff (%)			
RMB mn	FY21E	FY22E	FY23E	FY21E	FY22E	FY22E	FY21E	FY22E	FY23E		
Revenue	89,477	113,572	141,583	99,297	119,037	140,600	-10%	-5%	1%		
Gross Profit	6,710	8,808	11,533	8,135	10,737	13,087	-18%	-18%	-12%		
Operating Profit	2,058	3,016	4,695	3,084	5,071	6,795	-33%	-41%	-31%		
Net profit	2,897	3,677	5,155	3,714	5,066	6,539	-22%	-27%	-21%		
EPS (RMB)	1.29	1.63	2.29	1.66	2.28	2.97	-23%	-28%	-23%		
Gross Margin	7.5%	7.8%	8.1%	8.2%	9.0%	9.3%	-0.7 ppt	-1.3 ppt	-1.2 ppt		
Operating Margin	2.3%	2.7%	3.3%	3.1%	4.3%	4.8%	-0.8 ppt	-1.6 ppt	-1.5 ppt		
Net Margin	3.2%	3.2%	3.6%	3.7%	4.3%	4.7%	-0.5 ppt	-1 ppt	-1 ppt		

Source: Company data, CMBIS estimates



Figure 4: Revenue breakdown

RMB mn	FY19	FY20	1H21	2H21E	FY21E	FY22E	FY23E
Assembly	26,847	31,152	30,471	26,029	56,500	74,000	92,000
YoY	53%	16%	208%	23%	81%	31%	24%
Component (metal/glass/plastic)	18,562	17,576	7,110	7,488	14,598	15,371	16,512
YoY	3%	-5%	-17%	-16%	-17%	5%	7%
Metal	13,000	10,996	5,476	2,611	8,087	6,626	6,886
Plastic	3,512	4,566	1,415	2,375	3,789	2,842	2,842
Glass/ceramic	1,500	3,000	1,725	3,975	5,700	5,130	5,643
Masks	-	12,100	446	643	1,089	484	212
YoY			-95%	-82%	-91%	-56%	-56%
E-cigarette	-	1,000	200	1,300	1,500	2,400	4,080
					50%	60%	70%
New intelligent	6,025	9,476	5,014	7,779	12,793	17,270	23,315
YoY	39%	57%	38%	33%	35%	35%	35%
Auto intelligent	1,594	1,817	1,290	1,708	2,998	4,047	5,464
YoY	34%	14%	90%	50%	65%	35%	35%
Total	53,028	73,121	44,531	43,647	89,477	113,572	141,583
YoY	29%	38%	42%	7%	22%	27%	25%

Source: Company data, CMBIS estimates

Figure 5: P&L forecast by interim

RMB mn	FY19	FY20	1H21	2H21E	FY21E	FY22E	FY23E
Revenue	53,028	73,121	44,531	44,947	89,477	113,572	141,583
YoY	29.2%	37.9%	41.9%	7.7%	22.4%	26.9%	24.7%
Cost of sales	(49,071)	(63,492)	(41,470)	(41,297)	(82,767)	(104,764)	(130,049)
Gross profit	3,957	9,629	3,061	3,650	6,710	8,808	11,533
GPM (%)	7%	13%	7%	8%	7%	8%	8%
YoY	-5.1%	143.3%	-47.4%	-38.7%	-30.3%	31.3%	30.9%
SG&A	(876)	(910)	(1,033)	(546)	(1,074)	(1,249)	(1,458)
% of rev	2%	1%	2%	1%	1%	1%	1%
R&D	(2,088)	(2,913)	325	(2,088)	(3,579)	(4,543)	(5,380)
% of rev	4%	4%	(1%)	5%	4%	4%	4%
Operating profit	994	5,806	(118)	1,015	2,058	3,016	4,695
OPM (%)	2%	8%	(0%)	2%	2%	3%	3%
YoY	-45%	484%	-103%	-71%	-65%	47%	56%
Net profit	1,598	5,441	1,643	1,254	2,897	3,677	5,155
NPM (%)	3%	7%	4%	3%	3%	3%	4%
YoY	-26%	241%	-34%	-58%	-47%	27%	40%

Source: Company data, CMBIS estimates

Figure 6: P&L forecast by interim

inguic of the forceast by in	O: ::::							
RMB mn	1Q20	2Q20	3Q20	4Q20	1Q21	2Q21	3Q21	4Q21E
Revenue	8,564	22,822	20,131	21,604	19,890	24,641	21,404	23,542
Gross profit	1064	3035	3386	2143	1282	1779	1,543	2,107
Net profit	657	1815	1862	1107	808	835	514	740
EPS (RMB)	0.29	0.81	0.82	0.49	0.36	0.37	0.23	0.33
Growth (YoY)								
Revenue	-18%	77%	33%	48%	132%	8%	6%	9%
Gross profit	27%	325%	219%	59%	20%	-41%	-54%	-2%
Net profit	69%	869%	312%	94%	23%	-54%	-72%	-33%
<u>Margin</u>								
Gross margin	12.4%	13.3%	16.8%	9.9%	6.4%	7.2%	7.2%	8.9%
Net margin	7.7%	8.0%	9.2%	5.1%	4.1%	3.4%	2.4%	3.1%

Source: Company data, CMBIS estimates



# **Valuation**

# Downgrade to HOLD with new TP HK\$26.44

We downgrade the stock to Hold with new TP HK\$ 26.44, to reflect lowered guidance and EPS revision. We derive our TP based on SOTP valuation to reflect BYDE's business diversification with different growth profiles and visibility.

Our TP is based on weighted-average target P/E multiple of 13.4x FY21E EPS. We assign 10x P/E to its assembly EMS business and 13x P/E for component/e-cigarette business, in-line with TW/HK-listed peers. We assign lower 8x for mask business to reflect its near-term growth potential amid COVID-19 outbreak.

Figure 7: BYDE - SOTP valuation

Business segment	% of FY22E Profit	FY22E EPS (RMB)	Target P/E
Assembly	17%	0.28	10x
Components	30%	0.49	13x
Masks	1%	0.02	8x
Others (smart, auto)	51%	0.84	20x
Total (RMB) /Implied P/E		1.63	13.4x
TP (HK\$)			26.44

Sources: Company data, CMBIS estimates

Figure 8: Peers' valuation

			Market Cap	Price	TP	Up/ Down	P/E	(x)	P/E	3 (x)	ROE	(%)
Company	Ticker	Rating	(US\$ mn)	(LC)	(LC)	-side	FY21E	FY22E	FY21E	FY22E	FY21E	FY22E
BYDE	285 HK	Buy	6,704	23.15	26.44	14%	14.9	11.8	2.6	2.3	11.8	13.2
Tongda	698 HK	Buy	311	0.25	*0.56	NA	3.1	3.4	0.2	0.2	7.7	6.5
AAC Tech	2018 HK	Hold	5,273	33.95	45.3	33%	17.6	15.9	1.6	1.5	9.1	10.3
TK Group	2283 HK	Buy	316	2.95	4.1	39%	4.6	4.6	1.9	1.9	41.7	21.2
Ju Teng	3336 HK	NR	205	1.33	NA	NA	7.8	6.7	0.2	0.2	3.1	3.6
Everwin	300115 CH	NR	2,629	14.02	NA	NA	19.9	12.7	2.3	2.1	10.5	16.2
Lens Tech	300433 CH	NR	16,515	21.27	NA	NA	18.0	14.0	2.3	2.0	13.4	15.2
Foxconn	2354 TT	NR	3,501	68.80	NA	NA	12.2	11.5	0.7	0.6	7.0	7.2
		NR	4,411	161.00	NA	NA	14.5	12.1	0.8	0.7	5.4	6.1


Source: Bloomberg, CMBIS estimates, \*TP under review

Figure 9: 12M forward P/E band



Source: Bloomberg, CMBIS estimates

Figure 10: 12M forward P/B band



Source: Bloomberg, CMBIS estimates



# **Financial Summary**

Income statement						Cash flow summary					
YE 31 Dec (RMB mn)	FY19A	FY20A	FY21E	FY22E	FY23E	YE 31 Dec (RMB mn)	FY19A	FY20A	FY21E	FY22E	FY23E
Revenue	53,028	73,121	89,477	113,572	141,583	Profit before taxation	1,696	6,221	3,218	4,179	5,858
COGS	(49,071)	(63,492)	(82,767)	(104,764)(	(130,049)	Depreciation	2,157	2,442	2,790	3,233	3,784
Gross profit	3,957	9,629	6,710	8,808	11,533	Change in working capital	(3,596)	(1,499)	722	(2,498)	(2,338)
·						Others	(20)	(708)	(251)	(430)	(632)
Selling and marketing	(257)	(237)	(268)	(341)	(326)	Net cash from operating	237	6,455	6,480	4,484	6,673
Administrative	(619)	(673)	(805)	(909)	(1,133)						
R&D	(2,088)	(2,913)	(3,579)	(4,543)	(5,380)	Capex	(3,140)	(2,632)	(3,221)	(4,089)	(5,097)
Other operating exp.						Other					
Operating profit	994	5,806	2,058	3,016	4,695	Net cash from investing	(3,140)	(2,632)	(3,221)	(4,089)	(5,097)
Financial cost	(31)	(71)	(71)	(71)	(71)	Dividend paid	(160)	(543)	(290)	(368)	(515)
Other income/(losses)	734	487	1,232	1,234	1,234		(31)	(71)	(71)	(71)	(71)
Pre-tax profit	1,696	6,221	3,218	4,179	5,858	Net cash from financing	(191)	(614)	(361)	(439)	(587)
Tax	(99)	(779)	(322)	(501)	(703)	Net change in cash	(3,095)	3,209	2,898	(44)	989
Minority interest	` -			-	-	Cash at beginning of the year	4,699	1,651	4,859	7,757	7,713
Net profit	1,598	5,441	2,897	3,677	5,155	0 0 ,	,	,	,	, -	,
p. o	•	-	-	•	•	Cash at the end of the year	1,651	4,859	7,757	7,713	8,702

Balance sheet						Key ratios					
YE 31 Dec (RMB mn)	FY19A	FY20A	FY21E	FY22E	FY23E	YE 31 Dec	FY19A	FY20A	FY21E	FY22E	FY23E
Current assets	17,082	25,250	29,473	36,165	42,478	Sales mix (%)					
Cash & equivalents	1,651	4,859	7,757	7,713	8,702	Phone and PC components	35	24	16	14	12
Account receivables	9,567	11,324	12,536	15,857	19,539	Assembly services	51	43	63	65	65
Inventories	5,453	8,656	8,769	12,184	13,826	Masks					
Short-term bank deposits	-	-	-	-	-	New intelligent products	11	13	14	15	16
Other current assets	411	411	411	411	411	Auto intelligent systems	3	2	3	4	4
						Growth (%)					
Non-current assets	9,950	10,123	10,515	11,293	12,487	Revenue	29.2	37.9	22.4	26.9	24.7
PPE	8,617	8,808	9,239	10,095	11,408	Gross profit	(5.1)	143.3	(30.3)	31.3	30.9
Deferred income tax	159	159	159	159	159	Operating profit	(45.4)	484.3	(64.6)	46.6	55.7
Other non-current assets	1,173	1,156	1,117	1,039	920	Net profit	(25.5)	240.6	(46.8)	27.0	40.2
Total assets	27,032	35,374	39,988	47,458	54,964						
						Profit & loss ratio (%)					
Current liabilities	10,399	13,860	15,906	20,145	23,130	Gross margin	7.5	13.2	7.5	7.8	8.1
Deferred income						Operating margin	1.9	7.9	2.3	2.7	3.3
Account payables	7,340	10,801	12,847	17,086	20,071	Net profit margin	3.0	7.4	3.2	3.2	3.6
Tax payable	108	108	108	108	108						
Other current liabilities	2,951	2,951	2,951	2,951	2,951	Balance sheet ratio					
						Net debt/total equity (x)	Net cash Net cash Net cash Net cash N			Net cash	
Non-current liabilities	639	639	639	639	639	Current ratio (x)	1.6	1.8	1.9	1.8	1.8
Deferred income	122	122	122	122	122	Receivable turnover days	58	52	49	46	46
Deferred tax liability	18	18	18	18	18	Inventory turnover days	38	41	38	37	37
Total liabilities	11,038	14,498	16,545	20,783	23,769	Payable turnover days	57	52	52	52	52
Share capital	4,052	4,052	4,052	4,052	4,052	Profitability (%)					
Reserves	12,937	17,836	20,443	23,752	28,392	ROE	9.4	24.9	11.8	13.2	15.9
Minority interest						ROA	5.9	15.4	7.2	7.7	9.4
Shareholders' equity	16,989	21,888	24,495	27,805	32,444						
Total equity and liabilities	28,027	36,386	41,039	48,588	56,213	Per share data (RMB)					
						EPS	0.71	2.41	1.29	1.63	2.29
						DPS	0.07	0.24	0.13	0.16	0.23

Source: Company data, CMBIS estimates



# **Disclosures & Disclaimers**

## **Analyst Certification**

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

### **CMBIS** Ratings

BUY

Stock with potential return of over 15% over next 12 months

HOLD

Stock with potential return of +15% to -10% over next 12 months

SELL

Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIS

OUTPERFORM MARKET-PERFORM UNDERPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months : Industry expected to underperform the relevant broad market benchmark over next 12 months

### CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

### **Important Disclosures**

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS and/or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS. Additional information on recommended securities is available upon request.

## For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc...) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

## For recipients of this document in the United States

CMBIS is not a registered broker-dealer in the United States. As a result, CMBIS is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

### For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.